Engineered Microorganisms for Localized Anti-Cancer Therapeutic Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges in effectively targeting poorly vascularized, hypoxic tumor regions and minimizing adverse effects on normal tissues, as they often result in autoimmune responses and toxicity due to systemic administration, and struggle with the immune system's tolerance to cancer cells.
Innovation Solution
Engineered microorganisms, such as bacteria and viruses, are designed to selectively target tumor sites, producing anti-cancer molecules locally to stimulate an immune response, thereby avoiding systemic toxicity and enhancing antitumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional cancer therapies are administered systemically, then therapeutic coverage is improved, but autoimmune toxicity and adverse effects on normal tissues worsen
Solution Approach 1:
The patent applies local quality by engineering microorganisms to selectively accumulate and produce immune modulators specifically at the tumor site rather than distributing the therapeutic agent systemically. This localized production concentrates the therapeutic effect where needed while minimizing exposure to healthy tissues, thereby reducing autoimmune toxicity and adverse effects on normal organs.
Solution Approach 2:
The patent uses engineered microorganisms as intermediaries to deliver immune modulators to the tumor microenvironment. These microorganisms act as living carriers that navigate to the tumor site and locally produce the therapeutic agents, serving as a mediator between systemic administration and localized action, thus achieving broad therapeutic coverage without systemic toxicity.
2Reliability
If immune checkpoint inhibitors are administered systemically, then anti-tumor immune response is improved, but immune-related adverse events worsen
Solution Approach 1:
The patent implements local quality by enabling engineered microorganisms to produce immune checkpoint inhibitors specifically within the tumor microenvironment. This localized production maintains effective concentrations of the inhibitor at the tumor site to stimulate anti-tumor immunity while preventing systemic circulation of the drug, thereby reducing immune-related adverse events in healthy organs.
Solution Approach 2:
The engineered microorganisms exhibit self-service by autonomously navigating to the tumor site and producing the therapeutic immune modulators in situ. This self-directed localized production eliminates the need for systemic drug circulation, achieving reliable anti-tumor immune response while minimizing harmful side effects.
3Productivity
If high doses of cancer therapies are administered, then therapeutic efficacy is improved, but adverse effects on healthy cells worsen
Solution Approach 1:
The patent applies local quality by engineering microorganisms to concentrate and produce high doses of immune modulators specifically at the tumor site. This localized high-dose production achieves potent therapeutic efficacy against cancer cells while preventing the systemic distribution that would cause adverse effects on healthy cells, thus decoupling therapeutic efficacy from systemic toxicity.
Data Source
AI summary
Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.